Figure 3.
Effect of asafoetida at the doses of 50 and 100 mg/kg on cSD, cS4L, cS5D, and cADD. *P < 0.05 indicates significant differences as compared to control. cSD cumulative seizure duration. cS4L cumulative stage 4 latency. cS5D cumulative stage 5 duration. cADD cumulative after discharge duration